Ye, N; Jardine, MJ; Oshima, M; Hockham, C; Heerspink, HJL; Agarwal, R; Bakris, G; ... Neuen, BL; + view all Ye, N; Jardine, MJ; Oshima, M; Hockham, C; Heerspink, HJL; Agarwal, R; Bakris, G; Schutte, AE; Arnott, C; Chang, TI; Górriz, JL; Cannon, CP; Charytan, DM; de Zeeuw, D; Levin, A; Mahaffey, KW; Neal, B; Pollock, C; Wheeler, DC; Di Tanna, GL; Cheng, H; Perkovic, V; Neuen, BL; - view fewer (2021) Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial. Circulation , 143 (18) pp. 1735-1749. 10.1161/CIRCULATIONAHA.120.048740.

Preview	Text 379911_0_merged_1590387662.pdf - Accepted Version Download (1MB) | Preview
Preview	Text 379911_0_unknown_upload_4950399_qnvnvl.pdf - Accepted Version Download (1MB) | Preview

Abstract

BACKGROUND: People with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) experience a high burden of hypertension but the magnitude and consistency of blood pressure (BP) lowering with canagliflozin in this population is uncertain. Whether the effects of canagliflozin on kidney and cardiovascular outcomes vary by baseline BP or BP lowering therapy is also unknown. METHODS: the CREDENCE trial randomized people with T2DM and CKD to canagliflozin or placebo. Post-hoc, we investigated the effect of canagliflozin on systolic BP across subgroups defined by baseline systolic BP, number of BP lowering drug classes, and history of apparent treatment-resistant hypertension (BP ≥130/80 mmHg while receiving ≥3 classes of BP lowering drugs, including a diuretic). We also assessed whether effects on clinical outcomes differed across these subgroups. RESULTS: The trial included 4,401 participants of whom 3,361 (76.4%) had baseline systolic BP ≥130 mmHg, and 1371 (31.2%) had resistant hypertension. By week 3, canagliflozin reduced systolic BP by 3.50mmHg (95% CI, -4.27 to -2.72), an effect maintained over the duration of the trial, with similar reductions across BP and BP lowering therapy subgroups (all P-interaction ≥0.05). Canagliflozin also reduced the need for initiation of additional BP lowering agents during the trial (HR 0.68, 95% CI 0.61-0.75). The effect of canagliflozin on kidney failure, doubling of serum creatinine, or death due to kidney or cardiovascular disease (HR 0.70, 95% CI 0.59-0.82) was consistent across BP and BP lowering therapy subgroups (all P-interaction ≥0.35), as were effects on other key kidney, cardiovascular and safety outcomes. CONCLUSION:

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item